On May 15, 2026, Prosight Management made a significant move by acquiring 468,463 shares of GeneDx Holdings, amounting to an estimated $42.72 million. This purchase, disclosed in a Securities and Exchange Commission (SEC) filing, increases Prosight’s stake in GeneDx to approximately 5.51% of its reportable assets under management, reflecting a strategic bet on the healthcare information services sector.
This acquisition comes at a time when GeneDx’s stock has underperformed, down 30% over the past year compared to the S&P 500’s 28% gain. Despite this decline, GeneDx reported a 17% year-over-year revenue increase to $102.3 million, with strong growth in exome and genome testing. However, the company has lowered its full-year revenue outlook, raising concerns among investors. Prosight’s confidence in GeneDx suggests a belief in the long-term value of its AI-driven diagnostics and genomic data capabilities, which could be pivotal as precision medicine gains traction.
For market professionals, Prosight’s investment highlights a potential undervaluation of GeneDx’s data assets, indicating that the market may not fully appreciate the company’s growth trajectory and its role in the evolving landscape of precision medicine.
Source: fool.com